【摘要】 目的:评价利拉鲁肽联合二甲双胍治疗2型糖尿病(T2DM)的临床疗效,探讨其临床应用价值。方法:将80例T2DM患者随机分为利拉鲁肽组与甘精胰岛素组,各40例,分别应用利拉鲁肽联合二甲双胍和甘精胰岛素联合二甲双胍治疗12周。以甘精胰岛素组为对照,观察利拉鲁肽联合二甲双胍对患者治疗前后空腹、餐后2 h胰岛素和餐后2 h C肽、空腹血糖(FBG)和餐后2 h血糖(2 h PG)、果糖胺(FMN)及糖化血红蛋白(Hb A1c)水平的影响。结果:两组患者治疗后的空腹胰岛素和空腹C肽均明显高于治疗前的空腹水平(P<0.05或P<0.01),且利拉鲁肽组餐后2 h C肽明显高于治疗前水平(P<0.05)。两组患者治疗后的FBG和2 h PG、FMN和Hb A1c均明显低于治疗前水平(P<0.05或P<0.01),组间比较差异则均无统计学意义(P>0.05),但利拉鲁肽组治疗后的FMN降低幅度大于甘精胰岛素组。结论:利拉鲁肽联合二甲双胍治疗T2DM具有良好的临床疗效,能够明显改善和促进胰岛B细胞分泌功能的恢复,治疗T2DM的短期临床疗效可能优于甘精胰岛素组。更多还原

【Abstract】 OBJECTIVE:To evaluate the clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus(T2DM),and to explore its clinical value. METHODS:80 T2 DM patients were randomized into liraglutide group and insulin glargine group. They were given liraglutide combined with metformin(40 cases)or insulin glargine combined with metformin(40 cases)for 12 weeks,respectively. The levels of fasting and 2 h postprandial insulin and C-peptide,FBG and 2 h PG,FMN and Hb A1 c in liraglutide group had been observed and compared with insulin glargine group. RESULTS:After treatment,the levels of fasting insulin and fasting C-peptide in 2 groups were significantly higher than before(P<0.05 or P<0.01),and the level of 2 h postprandial C-peptide in liraglutide group was significantly higher than before(P<0.05);the levels of FBG,2h PG,FMN and Hb A1 c in 2 groups were significantly lower than before(P<0.05 or P<0.01);there was no statistical significance(P>0.05);while the decrease of FMN in liraglutide group was greater than in insulin glargine group. CONCLUSIONS:For T2 DM patients,liraglutide combined with metformin could improve and promote islet β-cell functions obviously,and its short-term clinical efficacy may be better than insulin glargine group for T2 DM.更多还原